KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Assets (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Assets for 18 consecutive years, with $40.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Assets rose 8.85% year-over-year to $40.9 billion; the TTM value through Mar 2026 reached $40.9 billion, up 8.85%, while the annual FY2025 figure was $40.6 billion, 7.41% up from the prior year.
  • Assets hit $40.9 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $40.6 billion in the prior quarter.
  • Across five years, Assets topped out at $40.9 billion in Q1 2026 and bottomed at $26.3 billion in Q1 2022.
  • Average Assets over 5 years is $34.1 billion, with a median of $34.4 billion recorded in 2024.
  • Year-over-year, Assets soared 48.26% in 2022 and then increased 5.91% in 2025.
  • Regeneron Pharmaceuticals' Assets stood at $29.2 billion in 2022, then rose by 13.23% to $33.1 billion in 2023, then increased by 14.15% to $37.8 billion in 2024, then grew by 7.41% to $40.6 billion in 2025, then increased by 0.76% to $40.9 billion in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $40.9 billion, $40.6 billion, and $40.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.